Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching

Table 5 Adverse events associated with regorafenib or cabometyx as second-line therapy

Adverse event	Cabozantinib (n = 28)	Regorafenib (n = 58)	P value
Fatigue and/or decreased appetite and/or weight loss, n (%)	22 (79)	46 (79)	1.0000
Grade 1-2/3-4	20 (89)/2 (11)	40 (85)/7 (15)	1.0000
Hand-foot skin, n (%)	9 (32)	16 (28)	0.8005
Grade 1-2/3-4	8 (89)/1 (11)	11 (69)/5 (31)	0.3644
Diarrhea, n (%)	11 (39)	13 (22)	0.1021
Grade 1-2/3-4	11 (100)/0	13 (100)/0	1.0000
Increased blood Bilirubin and/or AST and/or ALT, n (%)	9 (32)	17 (29)	0.8063
Grade 1-2/3-4	4 (44)/5 (56)	11 (65)/6 (35)	0.4185
Hypertension, n (%)	6 (21)	12 (21)	1.0000
Grade 1-2/3-4	5 (83)/1 (17)	11 (92)/1 (8)	1.0000
Other disorders1, n (%)	14 (50)	19 (33)	0.1234
Grade 1-2/3-4	12 (86)/2 (14)	18 (95)/1 (5)	0.5612
Interruptions, n (%)	12 (43)	31 (53)	0.3573
Dose reduction, n (%)	23 (82)	49 (84)	0.7646

¹Other disorders: Oral mucositis, dysphonia, decrease in platelet count, muscular pain, ascites.

AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.